Patents by Inventor George Tachas

George Tachas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION
    Publication number: 20140206746
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 24, 2014
    Applicant: Antisense Therapeutics Limited
    Inventor: George Tachas
  • Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
    Patent number: 8765700
    Abstract: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin ?4 comprising administering to the animal a composition comprising from. 0.001 to 1000 ?g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin ?4.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 1, 2014
    Assignee: Antisense Therapeutics Ltd.
    Inventors: George Tachas, James G. Karras, Susan Gregory, Jeffrey R. Crosby, Kenneth W. Dobie, Frank C. Bennett
  • Methods for treating multiple sclerosis using antisense oligonucleotides
    Patent number: 8759314
    Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: June 24, 2014
    Assignees: Antisense Therapeutics Limited, Teva Pharmaceutical Industries, Ltd.
    Inventors: Ety Klinger, Shoshi Tessler, Hallak Hussein, George Tachas, Mark Paul Diamond
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8637484
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 28, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8623836
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: January 7, 2014
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Ltd.
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • METHODS FOR TREATING MULTIPLE SCLEROSIS USING ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20130345293
    Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.
    Type: Application
    Filed: March 22, 2013
    Publication date: December 26, 2013
    Applicants: TEVA PHARMACEUTICAL INDUSTRIES, LTD., ANTISENSE THERAPEUTICS LIMITED
    Inventors: Ety Klinger, Shoshi Tessler, Hussein Hallak, George Tachas, Mark Paul Diamond
  • METHOD FOR MOBILIZING STEM AND/OR PROGENITOR CELLS
    Publication number: 20130323196
    Abstract: The present disclosure relates to methods for mobilizing stem and/or progenitor cells which are VLA-4 positive to the peripheral blood of a subject or from a tissue. The method comprises administering to the subject or tissue an effective amount of an antisense compound to VLA-4.
    Type: Application
    Filed: September 19, 2011
    Publication date: December 5, 2013
    Applicant: ANTISENSE THEREAPEUTICS LTD
    Inventor: George Tachas
  • Methods for treating multiple sclerosis using antisense oligonucleotides
    Patent number: 8415314
    Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 9, 2013
    Assignees: Antisense Therapeutics Limited, Teva Pharmaceutical Industries, Ltd.
    Inventors: Ety Klinger, Shoshi Tessler, Hussein Hallak, George Tachas, Mark Paul Diamond
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 8299039
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: October 30, 2012
    Assignees: Isis Pharmaceuticals, Inc., Antisense Therapeutics Limited
    Inventors: George Tachas, Kenneth W Dobie, Ravi Jain, Christopher I Belyea, Mark A Heffernan
  • MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION
    Publication number: 20110092572
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 21, 2011
    Applicants: Antisense Therapeutics Limited, Isis Pharmaceuticals, Inc.
    Inventors: George Tachas, Kenneth W. Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Methods for treating multiple sclerosis using antisense oligonucleotides
    Publication number: 20100119480
    Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.
    Type: Application
    Filed: June 23, 2009
    Publication date: May 13, 2010
    Inventors: Ety Klinger, Shoshi Tessler, Hussein Hallak, George Tachas, Mark Paul Diamond
  • MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION IN CANCER
    Publication number: 20100093832
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.
    Type: Application
    Filed: October 13, 2009
    Publication date: April 15, 2010
    Inventors: George Tachas, Lynne Maree Atley, Christopher J. Wraight
  • Inhibition of gastric acid production and/or secretion
    Patent number: 7501400
    Abstract: The present invention relates to methods for the treatment or prevention of gastric acid disturbances and for reducing the breakdown of acid sensitive agents in the gastrointestinal tract. The present invention also relates to a method for transfecting parietal cells in vivo. The present invention also relates to synthetic oligonucleotides which may be used in these methods.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: March 10, 2009
    Inventor: George Tachas
  • Topical administrations of antisense compounds to vla-4 for the treatment of respiratory conditions
    Publication number: 20090029931
    Abstract: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin ?4 comprising administering to the animal a composition comprising from. 0.001 to 1000 ?g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin ?4.
    Type: Application
    Filed: October 20, 2005
    Publication date: January 29, 2009
    Inventors: George Tachas, James C. Karras, Susan Gregory, Jeffrey R. Crosby, Kenneth W. Dobie, C. Frank Bennett
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Publication number: 20060178325
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 10, 2006
    Inventors: George Tachas, Kenneth Dobie, Christopher Belyea, Mark Heffernan, Ravi Jain
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Publication number: 20050282761
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: August 25, 2004
    Publication date: December 22, 2005
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Publication number: 20040253723
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: February 26, 2004
    Publication date: December 16, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: George Tachas, Kenneth W. Dobie, Ravi Jain, Christopher Belyea, Mark A. Heffernan